JonathanEdwardBrammerMD
Hematology • Columbus, OHMedical Resident, Medicine, Baylor College of Medicine
Dr. Brammer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
460 W 10th Ave
5th Floor
Columbus, OH 43210Phone+1 614-366-6963Fax+1 614-293-4812- Is this information wrong?
Education & Training
Oregon Health & Science UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015
Baylor College of MedicineResidency, Internal Medicine, 2009 - 2012
Northeast Ohio Medical UniversityClass of 2009
Certifications & Licensure
OR State Medical License 2012 - Present
OH State Medical License 2016 - 2025
TX State Medical License 2011 - 2019
Publications & Presentations
PubMed
- A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma.Muhamad Alhaj Moustafa, Jeremy L Ramdial, Athanasios Tsalatsanis, Farhad Khimani, Bhagirathbhai Dholaria, Leyla Bojanini, Taylor Brooks, Jasmine Zain, N Nora Bennani, ...> ;Transplantation and Cellular Therapy. 2024 Feb 29
- Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas.Waller, A., Dotson, E., McLaughlin, E., Braunstein, Z., Hanel, W., Reneau, J., Addison, D., Porcu, P., Brammer, J.> ;Leukemia & Lymphoma. 2024 Mar 1
- 3 citationsTargeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.Bradley Haverkos, Onder Alpdogan, Robert Baiocchi, Jonathan E Brammer, Tatyana A Feldman, Marcelo Capra, Elizabeth A Brem, Santosh Nair, Phillip Scheinberg, Juliana Pe...> ;Blood Advances. 2023 Oct 24
- Join now to see all
Abstracts/Posters
- Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin LymphomaJonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic LymphomaJonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...Jonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Blockade of IL-15 Utilizing Bnz-1, a Selective _-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemi...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
New Three-Drug Combo Stimulates 'Master Cancer Killer' Cells, Boosts Immune System of Patients Undergoing Stem Cell TransplantationJanuary 3rd, 2022
Duvelisib Tested in Rare Lymphoma SubtypeMarch 4th, 2020
Promising Cancer Treatment Which Made Patients Worse Shows How Far There Is to GoJune 7th, 2018- Join now to see all
Hospital Affiliations
The OSUCCC - JamesColumbus, Ohio
Ohio State University Wexner Medical CenterColumbus, Ohio
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
